Regen BioPharma, Inc. announced initiation of a series of phased experiments to begin the process of moving its CAR-T cell de-differentiation approach through pre-clinical...
Regen BioPharma, Inc. announced development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a...
Regen BioPharma, Inc., announced the filing with the United States Patent and Trademark Office of a provisional patent application covering utilization of dendritic cell...
Regen BioPharma, Inc. is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase...
